SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focusing on severe rare diseases and cancer, has announced its upcoming second quarter 2024 financial results report. The company will host a live conference call and webcast on Wednesday, August 7, 2024, at 8:30 a.m. ET to present the results and discuss recent business updates. Interested parties can join the webcast to view the presentation slides or pre-register for the conference call to participate by phone. A replay of the webcast will be available for a time on the company's investor relations website.
SpringWorks Therapeutics (Nasdaq: SWTX), un'azienda biofarmaceutica in fase commerciale che si concentra su malattie rare gravi e cancro, ha annunciato il suo imminente rapporto sui risultati finanziari del secondo trimestre 2024. L'azienda ospiterà una conferenza telefonica e un webcast dal vivo mercoledì 7 agosto 2024, alle 8:30 ora orientale, per presentare i risultati e discutere gli aggiornamenti aziendali recenti. Le parti interessate possono unirsi al webcast per visualizzare le diapositive della presentazione oppure pre-registrarsi per la conferenza telefonica per partecipare tramite telefono. Una registrazione del webcast sarà disponibile per un certo periodo sul sito web delle relazioni con gli investitori dell'azienda.
SpringWorks Therapeutics (Nasdaq: SWTX), una compañía biofarmacéutica en etapa comercial enfocada en enfermedades raras severas y cáncer, ha anunciado su próximo informe de resultados financieros del segundo trimestre de 2024. La empresa llevará a cabo una llamada de conferencia y webcast en vivo el miércoles 7 de agosto de 2024, a las 8:30 a.m. ET, para presentar los resultados y discutir las actualizaciones recientes del negocio. Las partes interesadas pueden unirse al webcast para ver las diapositivas de la presentación o preregistrarse para la llamada de conferencia y participar por teléfono. Se dispondrá de una grabación del webcast durante un tiempo en el sitio web de relaciones con inversionistas de la compañía.
SpringWorks Therapeutics (Nasdaq: SWTX)는 중증 희귀 질환 및 암에 중점을 둔 상업 단계의 생명공학 회사로, 2024년 2분기 재무 결과 보고서를 발표할 예정이라고 발표했습니다. 이 회사는 2024년 8월 7일 수요일 오전 8시 30분 ET에 결과를 발표하고 최근 비즈니스 업데이트를 논의하기 위한 실시간 컨퍼런스 콜 및 웹캐스트를 개최합니다. 관심 있는 분들은 웹캐스트에 참여하여 프레젠테이션 슬라이드를 보거나 전화로 참여하기 위해 컨퍼런스 콜에 미리 등록할 수 있습니다. 웹캐스트의 재생은 회사의 투자자 관계 웹사이트에서 일정 기간 동안 사용할 수 있습니다.
SpringWorks Therapeutics (Nasdaq: SWTX), une entreprise biopharmaceutique en phase commerciale spécialisée dans les maladies rares sévères et le cancer, a annoncé son prochain rapport sur les résultats financiers du deuxième trimestre 2024. L'entreprise organisera une conférence téléphonique et un webcast en direct le mercredi 7 août 2024, à 8h30, heure de l'Est, pour présenter les résultats et discuter des mises à jour récentes de l'entreprise. Les parties intéressées peuvent participer au webcast pour voir les diapositives de la présentation ou pré-enregistrer pour la conférence téléphonique afin de participer par téléphone. Un replay du webcast sera disponible pendant un certain temps sur le site Web des relations avec les investisseurs de l'entreprise.
SpringWorks Therapeutics (Nasdaq: SWTX), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf schwere seltene Krankheiten und Krebs konzentriert, hat seinen bevorstehenden Finanzergebnisbericht für das zweite Quartal 2024 angekündigt. Das Unternehmen wird am Mittwoch, den 7. August 2024, um 8:30 Uhr ET eine Live-Konferenzschaltung und Webcast veranstalten, um die Ergebnisse zu präsentieren und aktuelle Geschäftsnachrichten zu besprechen. Interessierte können am Webcast teilnehmen, um die Präsentationsfolien anzusehen, oder sich im Voraus für die Telefonkonferenz registrieren, um telefonisch teilzunehmen. Eine Aufzeichnung des Webcasts wird für eine gewisse Zeit auf der Investor-Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
STAMFORD, Conn., July 23, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Wednesday, August 7, 2024 to report its second quarter financial results and discuss recent business updates.
To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Kim Diamond
Vice President, Communications and Investor Relations
Phone: 203-561-1646
Email: kdiamond@springworkstx.com
Samantha Hilson Sandler
Senior Director, Investor Relations
Phone: 203-461-5501
Email: samantha.sandler@springworkstx.com
FAQ
When will SpringWorks Therapeutics (SWTX) report its Q2 2024 financial results?
What time is SpringWorks Therapeutics' (SWTX) Q2 2024 earnings call scheduled for?
How can investors access SpringWorks Therapeutics' (SWTX) Q2 2024 earnings webcast?
Will SpringWorks Therapeutics (SWTX) provide a replay of its Q2 2024 earnings call?
